InspireMD Inc
Change company Symbol lookup
Select an option...
NSPR InspireMD Inc
PGNRF Pan Global Resources Inc
GLDD Great Lakes Dredge & Dock Corp
CLVT Clarivate PLC
WTER Alkaline Water Company Inc
DSL DoubleLine Income Solutions Fund
GCO Genesco Inc
MPAA Motorcar Parts of America Inc
FMCKL Federal Home Loan Mortgage Corp
FNHC Fednat Holding Co
Go

Health Care : Health Care Equipment & Supplies | Small Cap Value
Based in Israel
Company profile

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Price
Delayed
$1.92
Day's Change
-0.005 (-0.26%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.97
Day's Low
1.92
Volume
(Light)

Today's volume of 9,457 shares is on pace to be much lighter than NSPR's 10-day average volume of 25,099 shares.

9,457

Display:

Providers:

UpdateCancel
6 providers
August 09, 2022
InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update

- Generated 47.8% growth in CGuard(TM) revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuard(TM) EPS, including a successful live case transmission - - Announced that endovascular pioneer Dr. Juan Parodi has...(Globe Newswire)

August 02, 2022
InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update

EQNX::TICKER_START (NASDAQ:NSPR), EQNX::TICKER_END - Conference call and webcast to be held at 8:30 a.m. EDT - InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard(TM) Embolic Prevention Stent System (EPS) device for the treatment of Carotid...(Globe Newswire)

July 14, 2022
InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

EQNX::TICKER_START (NASDAQ:NSPR), EQNX::TICKER_END InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard(TM) Embolic Prevention System (EPS) for the prevention of stroke, today announced the appointment of endovascular pioneer Dr. Juan Parodi as a...(Globe Newswire)

June 09, 2022
InspireMD Provides Highlights from Recent Presentations and Live Case Transmission at LINC 2022

EQNX::TICKER_START (NASDAQ:NSPR), EQNX::TICKER_END InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard(TM) Embolic Prevention System (EPS) for the prevention of stroke, today provided the following highlights from multiple presentations and live...(Globe Newswire)

June 02, 2022
InspireMD's CGuard(TM) Embolic Prevention Stent System to be Featured in Clinical Presentations and a Live Case Transmission at LINC 2022

EQNX::TICKER_START (NASDAQ:NSPR), EQNX::TICKER_END InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard(TM) Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will participate in the Leipzig...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.